Lake Bleu Capital (Hong Kong) Limited

Lake Bleu Capital (Hong Kong) Limited

Charles Chen established Lake Bleu Capital in Hong Kong in 2015 after a career in investment banking. The firm operates as a single-family office, managing the wealth generated from proprietary investments in healthcare and technology. Lake Bleu Capital focuses on healthcare and technology, with a particular emphasis on biotechnology and pharmaceutical companies in Asia. The firm has taken positions in companies like BeiGene and Zai Lab, often participating in pre-IPO and IPO rounds. Its strategy includes direct investments in publicly listed and private companies across the region, with a geographic focus on Hong Kong, mainland China, and broader Asia (per Reuters, 2021). The firm's team size and exact AUM remain undisclosed. No additional offices beyond Hong Kong have been publicly identified. In 2021, Lake Bleu Capital was reported to have been an anchor investor in the IPO of BeiGene, a cancer drug developer based in China (per Bloomberg, 2021). Lake Bleu Capital's structure as a single-family office allows it to maintain a concentrated, high-conviction portfolio in healthcare and technology. Its focus on pre-IPO and IPO-stage companies in Asia distinguishes it from broader multi-asset family offices, which often diversify across asset classes and geographies.